Skip to content

Calumet, Inc. CLMT Warrants And Rights Outstanding

Warrants And Rights Outstanding at other companies

Plug Power logo
Plug PowerPLUG
$106.96M
Toast logo
ToastTOST
$11M-42.1%
Joby Aviation logo
Joby AviationJOBY
$29.46M-51.9%
Calumet, Inc. logo
Calumet, Inc.CLMT
$7.8M0.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$308.19M+3,316%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
312.5K0.0%

Other financials

Income statement

See full
Revenue$1.0B+3.6%
Gross profit-$87.5M-7.5%
Operating income-$171.3M-252%
Net income-$317.0M-95.7%
EPS (diluted)-$3.64-94.7%

Balance sheet

See full
Cash & equivalents$138.6M+12.3%
Total debt$2.3B-9.0%
Total equity-$1.0B-21.0%
Total assets$2.8B-2.4%

Cash flow

See full
Operating cash flow-$86.2M-194%
CapEx$13.2M-25.0%
Free cash flow-$99.4M-112%

Valuation

See full
Market cap$2.86B+185%
Enterprise value$5.06B+50.3%
P/S0.7×+0.4×

Profitability

See full
Gross margin5.8%+4.1pp
Operating margin4.8%
Net margin-4.5%-1.4pp
FCF margin0.1%

Returns & leverage

See full
Return on equity19.8%
Debt / equity-2.2×
Current ratio-0.1×

Where this comes from

Reported directly by Calumet, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WarrantsAndRightsOutstanding.

The official record: Calumet, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Calumet, Inc.'s warrants and rights outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Calumet, Inc.'s warrants and rights outstanding?
Calumet, Inc. (CLMT) reported warrants and rights outstanding of $7.8M in Q1 2026.
How has Calumet, Inc.'s warrants and rights outstanding changed year-over-year?
Calumet, Inc.'s warrants and rights outstanding decreased by 0.0% year-over-year, from $7.8M to $7.8M.
What does warrants and rights outstanding mean?
This represents the total value or count of outstanding warrants and rights that grant holders the option to purchase equity in the company at a predetermined price. These instruments represent potential future dilution for existing shareholders upon exercise. Analyzing this metric is critical for understanding the company's fully diluted share count and long-term capital structure implications.